Drugs & TargetsFree FDA expands approval of Imfinzi to reduce the risk of NSCLC progressing February 23, 2018Vol.44 No.08
FreeTrials & Tribulations Diversity within Diversity: Lessons from the Latinos of South Texas February 23, 2018Vol.44 No.08By Amelie G. Ramirez and Ruben A. Mesa
FreeIn Brief Frederick Schnell named to new post of COA medical director February 23, 2018Vol.44 No.08
FreeIn Brief Richard Barakat to lead Northwell Health cancer services, research February 23, 2018Vol.44 No.08
FreeIn Brief Denis Guttridge named director of MUSC Darby Children’s Research Institute, associate director at Hollings February 23, 2018Vol.44 No.08
Conversation with The Cancer LetterFree UT Health San Antonio’s link with MD Anderson goes live; How does it work? February 23, 2018Vol.44 No.08By Paul Goldberg
Conversation with The Cancer LetterFree His six-month “listening tour” almost over, Sharpless discusses his vision for NCI February 23, 2018Vol.44 No.08By Paul Goldberg
FreeTrials & Tribulations A Cancer Patient’s War on Cancer February 16, 2018Vol.44 No.07By C. Anthony "Tony" Blau
Clinical RoundupFree Opdivo-Yervoy combination demonstrates clinical activity in previously treated metastatic colorectal cancer January 26, 2018Vol.44 No.04
